Search Results

PINC AI™ Applied Sciences, a division of Premier, Inc., and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are expanding their existing collaboration to help shape the future of healthcare research, advance clinical trial operations, and increase trial diversity and equity – aiming to accelerate the development of novel therapies and products for improved patient outcomes.

Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced consolidated financial results for its second fiscal quarter ended March 31, 2024.

LANGaware, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier’s (NASDAQ: PINC) PINC AI™ Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, and Alphazyme LLC, a Maravai LifeSciences company and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies’ previously announced Linea™ RNAP manufacturing scale-up agreement.

Applied DNA Sciences, Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled “Compositions and Methods for RNA Synthesis.”